A5017475053- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Renal and related cancers
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Urologic and reproductive health conditions
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Genital Health and Disease
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Renal and Vascular Pathologies
- DNA Repair Mechanisms
- Multiple and Secondary Primary Cancers
- Sexual Differentiation and Disorders
- Immunotherapy and Immune Responses
- Enhanced Recovery After Surgery
- Pediatric Urology and Nephrology Studies
- MRI in cancer diagnosis
- Ferroptosis and cancer prognosis
Moffitt Cancer Center
2016-2025
Emory University
2023
Winship Cancer Institute
2023
The University of Texas Southwestern Medical Center
2022
Harold C. Simmons Comprehensive Cancer Center
2022
Bristol-Myers Squibb (Germany)
2022
Astellas Pharma (China)
2022
AstraZeneca (Finland)
2022
Janssen (Belgium)
2022
AstraZeneca (Poland)
2022
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on clinical presentation and workup of suspected bladder cancer, treatment non–muscle-invasive urothelial metastatic cancer because important updates have recently been made to these sections. Some include recommendations optimal event a bacillus Calmette-Guérin (BCG) shortage details about biomarker testing advanced or disease. The systemic therapy second-line subsequent...
To determine if obesity is associated with higher prostate specific antigen recurrence rates after radical prostatectomy (RP), and to explore racial differences in body mass index (BMI) as a potential explanation for the disparity outcome between black white men.
Urothelial tumors represent a spectrum of diseases with range prognosis. After diagnosis is established at any point within the urothelial tract, patient remains risk for developing new lesion different or same location and similar more advanced stage. Continued monitoring recurrence an essential part management, because most recurrences are superficial can be managed endoscopically. Within each category disease, refined methods to determine prognosis guide based on molecular staging, under...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.
The NCCN Guidelines for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer other urinary tract cancers (upper tumors, urothelial carcinoma prostate, primary urethra). These Insights summarize panel discussion behind recent important updates to guidelines regarding treatment non–muscle-invasive cancer, including how treat in event a bacillus Calmette-Guérin (BCG) shortage; new roles immune checkpoint inhibitors non–muscle...
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These Insights discuss important updates to 2018 version guidelines, including implications 8th edition AJCC Staging Manual on treatment muscle-invasive cancer incorporating newly approved immune checkpoint inhibitor therapies into options locally advanced or metastatic disease.
Bladder cancer, the sixth most common cancer in United States, is commonly of urothelial carcinoma histologic subtype. The clinical spectrum bladder divided into 3 categories that differ prognosis, management, and therapeutic aims: (1) non-muscle-invasive (NMIBC); (2) muscle invasive, nonmetastatic disease; (3) metastatic cancer. These NCCN Guidelines Insights detail recent updates to for Cancer, including changes fifth edition WHO Classification Tumours: Urinary Male Genital Tumours how...
BackgroundPatients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist Nogapendekin alfa inbakicept (NAI), also known as N-803, may act synergistically BCG to elicit durable complete responses (CRs) in this patient population.MethodsIn open-label, multicenter study, patients BCG-unresponsive carcinoma situ (CIS) or without Ta/T1 papillary disease were treated...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 May 2003Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated Radical Prostatectomy JASON C. MASSENGILL, LEON SUN, JUDD W. MOUL, HONGYU WU, DAVID G. McLEOD, CHRISTOPHER AMLING, RAYMOND LANCE, JOHN FOLEY, WADE SEXTON, LEO KUSUDA, ANDREW CHUNG, DOUGLAS SODERDAHL, and TIMOTHY DONAHUE MASSENGILLJASON MASSENGILL More articles by this author , SUNLEON SUN MOULJUDD MOUL...
Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there virtually no published literature comparing HT to observation in clinical setting. The goal this study was examine Department Defense Center Prostate Disease Research observational database compare outcomes men who experienced PSAR after radical prostatectomy by early versus delayed use and a risk stratified approach.Of 5,382 underwent primary (RP),...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2004Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence Cancer After Radical Prostatectomyis companion ofEarly Prostatectomy JUDD W. MOUL, HONGYU WU, LEON SUN, DAVID G. McLEOD, CHRISTOPHER AMLING, TIMOTHY DONAHUE, LEO KUSUDA, WADE SEXTON, KEITH O'REILLY, JAVIER HERNANDEZ, ANDREW CHUNG, and DOUGLAS SODERDAHL MOULJUDD MOUL , WUHONGYU WU SUNLEON SUN McLEODDAVID McLEOD AMLINGCHRISTOPHER AMLING...
Squamous cell carcinoma of the penis represents approximately 0.5% all cancers among men in United States and other developed countries. Although rare, it is associated with significant disfigurement, only half patients survive beyond 5 years. Proper evaluation both primary lesion lymph nodes critical, because nodal involvement most important factor survival. The NCCN Clinical Practice Guidelines Oncology for Penile Cancer provide recommendations on diagnosis management this devastating...
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with alone for patients bladder cancer. Although gemcitabine cisplatin has become a standard NAC regimen, dose-dense combination of methotrexate, vinblastine, doxorubicin, and (ddMVAC) is being adopted at some institutions.To assess the association neoadjuvant ddMVAC vs regimens downstaging overall among treated cancer.Cross-sectional analysis data extracted from medical records consecutive sample, after...
These NCCN Guidelines Insights discuss the major recent updates to for Bladder Cancer based on review of evidence in conjunction with expert opinion panel. Recent include (1) refining recommendation intravesical bacillus Calmette-Guérin, (2) strengthening recommendations perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy locally advanced or metastatic disease. further factors that affect integration these clinical practice.
Patients with metastatic renal cell cancer (mRCC) who respond to upfront immune checkpoint inhibitor (ICI) combination therapies may be treated cytoreductive nephrectomy (CN) remove radiographically viable primary tumors. Early data for post-ICI CN suggested that ICI induce desmoplastic reactions in some patients, increasing the risk of surgical complications and perioperative mortality. We evaluated outcomes 75 consecutive patients at four institutions from 2017 2022. Our cohort had minimal...
Sarcoma of prostate origin is rare. Historically, long-term survival rates for adult patients with sarcoma are poor. We analyzed the experience 1 institution during last 3 decades.The records 21 were reviewed to identify symptoms at presentation, diagnostic procedures, presence and development metastases, staging evaluation, histological subtype, grade size primary tumor, treatment sequence, including surgery, preoperative postoperative therapies. Several clinicopathological variables...
To assess the potential complications associated with inguinal lymph node dissection (ILND) across international tertiary care referral centres, and to determine prognostic factors that best predict development of these complications.A retrospective chart review was conducted four cancer centres. The study population 327 patients underwent diagnostic/therapeutic ILND. endpoint overall incidence their respective severity (major/minor). Clavien-Dindo classification system used standardize...